Harpreet Singh, PhD

Immatics Biotechnologies GmbH , CEO

Dr Harpreet Singh co-founded Immatics in 2000. Since then he has served as Managing Director and Chief Scientific Officer of Immatics Biotechnologies GmbH, helping to grow the company from a start-up to an established biotech. He is dedicated to translating pioneering scientific discoveries into highly innovative cancer immunotherapeutics with clinical utility. Dr Singh has played a leading role in raising over US$200m of venture capital funding over several financing rounds. Since 2015, Dr Singh is President & CEO of Immatics US, Inc. overseeing all operations of Immatics in Houston, Texas as to develop next-generation Adoptive Cell Therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas. Dr Singh is the inventor on numerous patents and patent applications and has co-authored approx. 30 publications in prestigious peer-reviewed journals including Nature Medicine, Nature Biotechnology, Lancet Oncology and Journal of Experimental Medicine, Brain and Blood. A scholar of Prof. Hans-Georg Rammensee, Dr Singh completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.